The DOI matches its Crossref record.
Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients
Abstract
BACKGROUND: Platinum-containing combination chemotherapy has resulted in improved survival rates in patients with advanced ovarian carcinoma, but the majority of the patients still die of their disease. It is therefore important to develop new non-cross-resistant drugs. Gemcitabine (2',2'-difluorodeoxycytidine) has shown a broad spectrum of antineoplastic activity in tumor cell cultures in vitro and in animal tumor models. Clinical activity also has been reported in a variety of solid tumor types. PURPOSE: Our purpose was to assess the clinical activity of gemcitabine in previously treated ovarian cancer patients and to further characterize the toxicity of the compound. METHODS: Gemcitabine (800 mg/m2) was given intravenously once a week for 3 consecutive weeks, followed by 1 week of rest. A maximum of two different prior treatment regimens was allowed. Response was assessed by pelvic examination and/or ultrasound and computed tomography scans every other course. RESULTS: Fifty patients were eligible; 35 (70%) had bulky disease (tumor greater than 5 cm in diameter). All patients had received prior platinum-containing combination chemotherapy. Forty-two patients were assessable for response. Eight (19%) of the 42 patients (95% confidence interval = 9%-34%) achieved a partial response, with a median response duration of 8.1 months (range, 4.4-12.5 months). All responders started treatment with gemcitabine within 6 months of prior treatment, and seven of the eight responders were resistant to first-line platinum-containing combination chemotherapy. Overall median time to progression was 2.8 months (range, 0.2 12.5 months), and overall median survival was 6.2 months (range, 0.2-26.0 months). Forty-eight patients were assessable for toxicity. Leukocytopenia and thrombocytopenia were the main toxic effects that caused dose omissions (27% and 14%, respectively) and dose reductions (37% and 21%, respectively). A transient mild flu-like syndrome occurred in 28% of the patients, and treatment-related peripheral edema developed in 22%. Grade 1 hematuria (53% of patients), grade 1-2 proteinuria (79% of patients), and liver toxicity that was mostly grade 1-2 (59% of patients) were also observed. CONCLUSIONS: Gemcitabine is a well-tolerated new drug with activity in platinum-resistant ovarian cancer patients. IMPLICATIONS: Confirmatory trials are needed, and the activity of gemcitabine in previously untreated patients should be assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael, J., Possinger, K., Phillip, P., Beykirch, M., Kerr, H., Walling, J., & Harris, A. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2731 · Cited by 338
Second-Line Treatment of Ovarian Cancer
Markman, M., & Bookman, M. A. (2000) · The Oncologist · doi:10.1634/theoncologist.5-1-26 · Cited by 296
Lorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
Recent advances in the treatment of epithelial ovarian cancer
Harries, M., & Kaye, S. B. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1715 · Cited by 54
Metadata
- Authors
- Lund, B., Hansen, O. P., Theilade, K., Hansen, M., & Neijt, J. P.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-10-19
- Volume
- 86
- Issue
- 20
- Pages
- 1530-1533
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2154737435
- Cited by
- 333
- References
- 0
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients. https://app.cochat.ai/papers/10.1093/jnci/86.20.1530
- The paper
- Lund, B., Hansen, O. P., Theilade, K., Hansen, M., & Neijt, J. P. (1994). Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/86.20.1530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.